Erstellt am 13 Oct 2016 13:31
Zuletzt geändert: 19 May 2020 10:12
- Pulmonale Hypertonie Forum - Patientenforum
- Selbsthilfeverein Primäre Pulmonale Hypertonie (PPH) e.V.
Literatur
Prognose, Therapie-Effekt
- Zheng YG, Ma H, Chen L, et al. Efficacy and safety of oral targeted therapies in pulmonary arterial hypertension: a meta-analysis of randomized clinical trials. Pulm Circ. 2018 Oct-Dec;8(4):2045894018798183.
Twenty-five trials with a total of 6847 participants were included in the meta-analysis. Oral targeted therapies were associated with significant risk reduction in clinical worsening compared with placebo (relative risk [RR] 0.64; 95% CI = 0.58-0.70; P < 0.001). This reduction in risk was driven by reduction in non-fatal endpoints, including PAH-related admissions to hospital (RR = 0.66; 95% CI = 0.56-0.76; P < 0.001), treatment escalation (RR = 0.43; 95% CI = 0.28-0.66; P < 0.001), and symptomatic progression (RR = 0.55; 95% CI = 0.48-0.64; P < 0.001), but not by reduction of mortality (RR = 0.87; 95% CI = 0.68-1.12; P = 0.215). Oral targeted therapies were also associated with improvement in 6-min walk distance (26.62 m; 95% CI = 20.54-32.71; P < 0.001) and World Health Organization functional class (RR = 1.36; 95% CI = 1.20-1.54; P < 0.001). The results of this meta-analysis showed the benefits of oral treatments on clinical worsening events in PAH. However, these oral agents did not show any survival benefit in the short-term follow-up.
- Gao XF, Zhang JJ, Jiang XM, et al. Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials. Patient Prefer Adherence. 2017 May 8;11:871-885.
Imatinib
- Rieg AD, Bünting NA, Cranen C, et al. Tyrosine kinase inhibitors relax pulmonary arteries in human and murine precision-cut lung slices. Respir Res. 2019 Jun 6;20(1):111.
- Sato H, Sugimura K, Miura M, et al. Beneficial Effects of Imatinib in a Patient with Suspected Pulmonary Veno-Occlusive Disease. Tohoku J Exp Med. 2019 Feb;247(2):69-73.
- Ogawa A, Miyaji K, Matsubara H. Efficacy and safety of long-term imatinib therapy for patients with pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Respir Med. 2017 Oct;131:215-219.
- Baumgart B, Guha M, Hennan J, et al. In vitro and in vivo evaluation of dasatinib and imatinib on physiological parameters of pulmonary arterial hypertension. Cancer Chemother Pharmacol. 2017 Apr;79(4):711-723.
- Frost AE, Barst RJ, Hoeper MM, et al. Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. J Heart Lung Transplant. 2015 Nov;34(11):1366-75.
- Pubmed-Suche nach Imatinib und "pulmonary arterial Hypertension" - Link funktioniert nicht in Internet Explorer oder Edge!
- Suchformel: ("pulmonary arterial hypertension"[MeSH Terms] OR ("pulmonary"[All Fields] AND "arterial"[All Fields] AND "hypertension"[All Fields]) OR "pulmonary arterial hypertension"[All Fields]) AND ("imatinib mesylate"[MeSH Terms] OR ("imatinib"[All Fields] AND "mesylate"[All Fields]) OR "imatinib mesylate"[All Fields] OR "imatinib"[All Fields])
Studien/Register:
In view of the manifold options for mono- and combination therapy that have now emerged for patients with pulmonary (arterial) hypertension (PH/PAH), controlled clinical trials can only provide part of the information needed for optimal management. In order to gather adequate data on PAH/PH treatment in routine clinical care, the ongoing COMPERA registry prospectively documents consecutive patients with newly initiated treatment of PAH/PAH since May 2007. The internet-based registry fulfills high quality standards through several measures (planned minimum centre contribution of at least 10 patients per year, automated plausibility checks of data at entry, queries, monitoring with source data verification in >50% of participating centers). It can be applied, among further purposes, for quality assurance: individual centers can confidentially compare their results with the combined outcome of other centers and the recommendations from guidelines. It is expected that the register contributes to optimization of specific drug therapy for PAH and PH.
Since July 2013, also children of any age can be documented (COMPERA-KIDS).
Die Beiträge in diesem Wiki zu "Erkrankungen und Behinderungen", gesundheitlichen Problemlagen und Indikationen erheben weder den Anspruch, umfassend noch hinsichtlich der Einsortierung in einer Rubrik immer unstrittig zu sein.
Die Beiträge sind aus sozialmedizinischem Blickwinkel und mit dem Schwerpunkt der sozialmedizinischen Begutachtung einsortiert. Aus der Einordnung in einer Rubrik resultiert weder eine Wertung noch eine objektive Feststellung hinsichtlich der Bedeutung einer gesundheitlichen Problemlage/Erkrankung.
Alle Darstellungen medizinischer Sachverhalte, Erkrankungen und Behinderungen und deren sozialmedizinische Einordnung und Kommentierungen hier im Wiki dienen nicht einer "letzt begründenden theoretisch-wissenschaftlichen Aufklärung", sondern sind frei nach Karl Popper "Interpretationen im Licht der Theorien."*
* Zitat nach: Bach, Otto: ''Über die Subjektabhängigkeit des Bildes von der Wirklichkeit im psychiatrischen Diagnostizieren und Therapieren''. In: Psychiatrie heute, Aspekte und Perspektiven, Festschrift für Rainer Tölle, Urban & Schwarzenberg, München 1994, ISBN 3-541-17181-2, (Zitat: Seite 1)
Alle medizinischen Aussagen und Informationen in diesem Wiki dienen nicht der medizinischen Beratung und können und sollen eine persönliche fachliche ärztliche Beratung nicht ersetzen!
Neue Seite anlegen